Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer.

ABSTRACT: Despite good responses to first-line treatment with platinum-based combination chemotherapy, most ovarian cancer patients will relapse and eventually develop platinum-resistant disease with poor prognosis. Although reports suggest that integrin-linked kinase (ILK) is a potential target for ovarian cancer treatment, identification of ILK downstream effectors has not been fully explored. The purpose of this study was to investigate the molecular and biological effects of targeting ILK in cisplatin-resistant ovarian cancer. Western blot analysis showed that phosphorylation levels of ILK were higher in cisplatin-resistant compared with cisplatin-sensitive ovarian cancer cells. Further immunohistochemical analysis of ovarian cancer patient samples showed a significant increase in phosphorylated

SUBMITTER: Reyes-Gonzalez JM 

PROVIDER: S-EPMC7226328 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature